Sugi Predict

Sugi Predict / Compounds / SCHEMBL249690

SCHEMBL249690

SCHEMBL249690

FC(F)c1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.50
▸ HTR2A P28223 1/20 0.41
▸ CYP1A2 P05177 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ CYP19A1 P11511 1/20 0.35
▸ KIF11 P52732 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ CYP2C19 P33261 1/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL662302 0.83 PGK1 (0.38) KIF11
SCHEMBL23430134 0.80 CYP1A2 (0.37) CYP2A6HTR2ACYP1A2ALDH1A1MAPK1
Bromide SCHEMBL9813321 0.79 NOTUM (0.37) KIF11
SCHEMBL15111083 0.79 CYP2A6 (0.47) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL25356061 0.77 ESR1 (0.52) ALOX15
SCHEMBL6017173 0.77 CYP2A6 (0.44) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL28920988 0.77 CYP2A6 (0.44) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL16426371 0.77 CYP2A6 (0.44) CYP2A6HTR2ACYP1A2ALDH1A1ALOX15
SCHEMBL15271014 0.76 APP (0.61) —
SCHEMBL17284823 0.76 PYCR1 (0.33) HTR2ACYP1A2ALDH1A1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104681-A1 NEW SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-21 — — WO disclosed
CN-117659017-B TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof 北京华益健康药物研究中心 2026-05-15 — — CN disclosed
US-12612409-B2 Pyrrolopyrimidines as CFTR potentiators CYSTIC FIBROSIS FOUNDATION (US) 2026-04-28 — — US disclosed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
EP-3897833-B1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2026-02-04 — — EP disclosed
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 — — US disclosed
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 — — US disclosed
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC 2025-06-05 — — US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 — — US disclosed
EP-4536362-A1 TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS Incyte Corporation (US) 2025-04-16 — — EP disclosed
US-20050288366-A1 Novel aminodicarboxylic acid derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-12-29 — — US disclosed
WO-2005115977-A1 PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS TANABE SEIYAKU CO., LTD. (JP) 2005-12-08 — — WO disclosed
US-6939990-B2 Derivatives of dicarboxylic acid having pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2005-09-06 — — US disclosed
US-20040110840-A1 Novel derivatives of dicarboxylic acid having pharmaceutical properties BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-06-10 — — US disclosed
EP-1368302-A1 NOVEL AMINO DICARBOXYLIC ACID DERIVATIVES Bayer Aktiengesellschaft (DE) 2003-12-10 — — EP disclosed
WO-2002070459-A1 NOVEL AMINO DICARBOXYLIC ACID DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2002-09-12 — — WO disclosed
US-6127383-A TREATMENT OF ARTERIOSCLEROSIS BAYER AKTIENGESELLSCHAFT (DE) 2000-10-03 — — US disclosed
US-5925645-A ARTERIOSCLEROSIS BAYER AKTIENGESELLSCHAFT (DE) 1999-07-20 — — US disclosed
EP-0449015-B1 Difluoromethyl compounds and liquid criystal medium MERCK PATENT GMBH (DE) 1998-07-01 — — EP disclosed
EP-0449015-A2 Difluoromethyl compounds and liquid criystal medium MERCK PATENT GmbH (DE) 1991-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS HTR2B, HTR1B, HTR5A CYP2A6 2996/4885HTR2A 9/4885CYP1A2 1903/4885
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B CYP2A6 3813/4885HTR2A 1857/4885CYP1A2 1947/4885
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 CYP2A6 3551/4885HTR2A 1774/4885CYP1A2 3302/4885
US-20040110840-A1 Novel derivatives of dicarboxylic acid having pharmaceutical properties SDHA, GOT2, MDH2 CYP2A6 694/4885HTR2A 3937/4885CYP1A2 788/4885
US-12612409-B2 Pyrrolopyrimidines as CFTR potentiators CFTR, CLCN2, SLC26A3 CYP2A6 465/4885HTR2A 3148/4885CYP1A2 2350/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 CYP2A6 105/4885HTR2A 1865/4885CYP1A2 50/4885
US-20050288366-A1 Novel aminodicarboxylic acid derivatives DDC, DAO, AADAT CYP2A6 160/4885HTR2A 3068/4885CYP1A2 141/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 CYP2A6 30/4885HTR2A 408/4885CYP1A2 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.